Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
332 GBX | -2.35% | -1.78% | +17.31% |
05-14 | Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies | AN |
05-14 | Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.31% | 3.68B | |
+35.01% | 709B | |
+31.03% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.38% | 239B | |
+9.27% | 211B | |
-3.44% | 203B | |
+10.77% | 171B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Transcript : Hutchison China MediTech Limited - Special Call